FY2027 EPS Estimate for Gilead Sciences Lowered by Analyst

Gilead Sciences, Inc. (NASDAQ:GILD) – Investment analysts at Erste Group Bank lowered their FY2027 earnings per share (EPS) estimates for shares of Gilead Sciences in a note issued to investors on Wednesday, August 5th. Erste Group Bank analyst H. Engel now expects that the biopharmaceutical company will earn $9.57 per share for the year, down from their prior estimate of $9.59. The consensus estimate for Gilead Sciences’ current full-year earnings is ($0.50) per share.

Several other research firms have also recently weighed in on GILD. HSBC raised Gilead Sciences from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $133.00 to $155.00 in a research report on Monday, July 6th. Cantor Fitzgerald restated an “overweight” rating and set a $155.00 price objective on shares of Gilead Sciences in a report on Wednesday, August 5th. Royal Bank Of Canada boosted their price target on Gilead Sciences from $120.00 to $123.00 and gave the company a “sector perform” rating in a research note on Wednesday, August 5th. Wall Street Zen lowered Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Finally, Morgan Stanley reduced their price objective on shares of Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating for the company in a report on Monday, July 27th. Twenty-five equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $158.04.

Gilead Sciences Stock Performance

Shares of GILD opened at $133.06 on Tuesday. The company has a market capitalization of $165.20 billion, a PE ratio of -49.84 and a beta of 0.32. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. Gilead Sciences has a one year low of $108.46 and a one year high of $157.29. The company’s fifty day moving average price is $129.45 and its 200 day moving average price is $136.34.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The firm had revenue of $7.80 billion during the quarter, compared to analysts’ expectations of $7.40 billion. During the same quarter in the prior year, the business earned $2.01 earnings per share. The company’s revenue was up 10.6% on a year-over-year basis.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be issued a dividend of $0.82 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.28 annualized dividend and a yield of 2.5%. Gilead Sciences’s dividend payout ratio is currently -122.85%.

Insider Buying and Selling at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $130.31, for a total value of $1,954,650.00. Following the completion of the sale, the chief executive officer directly owned 592,133 shares of the company’s stock, valued at approximately $77,160,851.23. This trade represents a 2.47% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $132.27, for a total value of $396,810.00. Following the completion of the transaction, the chief financial officer owned 173,191 shares in the company, valued at approximately $22,907,973.57. This represents a 1.70% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 82,000 shares of company stock worth $10,641,790. Insiders own 0.30% of the company’s stock.

Hedge Funds Weigh In On Gilead Sciences

Several institutional investors have recently modified their holdings of GILD. Persistent Asset Partners Ltd acquired a new position in Gilead Sciences during the 2nd quarter worth approximately $25,000. Strategic Investment Solutions Inc. IL bought a new stake in shares of Gilead Sciences in the fourth quarter worth $25,000. Vermillion & White Wealth Management Group LLC boosted its holdings in Gilead Sciences by 71.4% during the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 85 shares during the last quarter. Quattro Advisors LLC bought a new position in Gilead Sciences in the fourth quarter valued at $26,000. Finally, Wealth Preservation Advisors LLC increased its stake in Gilead Sciences by 60.0% in the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 81 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.